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Understanding the functional effects of the wide-range of aberrant genetic characteristics
associated with the human chromosome 8q24 region in cancer remains daunting due to
the complexity of the locus. The most logical target for study remains the MYC proto-
oncogene, a prominent resident of 8q24 that was ﬁrst identiﬁed more than a quarter of a
century ago. However, many of the ampliﬁcations, translocation breakpoints, and viral inte-
gration sites associated with 8q24 are often found throughout regions surrounding large
expanses of the MYC locus that include other transcripts. In addition, chr.8q24 is host to
a number of single nucleotide polymorphisms associated with cancer risk. Yet, the lack of
a direct correlation between cancer risk alleles and MYC expression has also raised the
possibility thatMYC is not always the target of these genetic associations.The 8q24 region
has been described as a “gene desert” because of the paucity of functionally annotated
genes located within this region. Here we review the evidence for the role of other loci
within the 8q24 region, most of which are non-coding transcripts, either in concert with
MYC or independent of MYC, as possible candidate gene targets in malignancy.
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INTRODUCTION
Genome wide association studies (GWAS) have identiﬁed a large
number of single nucleotide polymorphisms (SNPs) in a segment
of about 2Mb mapping to human chromosome 8q24 (chr.8q24)
that are linked to susceptibility for different diseases including
cancers of the prostate, breast, esophagus, head and neck, ovar-
ian, colon, and pancreas (Easton and Eeles, 2008; Grisanzio and
Freedman, 2010; Figure 1). One gene found within this chr.8q24
region, MYC, stands out as the most likely candidate to be func-
tionally linked to these cancer risk-associated SNPs given its well
deﬁned role as an oncogenic transcription factor (Meyer et al.,
2006). In addition, toGWAS linkage, there are several other cancer-
associated features of this region of chr.8q24 (128.0–130.0Mb)
that serve to further establish the signiﬁcance of 8q24 in driving
tumor development that also complicates its’ study as well. While
MYC is recognized to be the most frequently ampliﬁed protein-
coding gene across all cancer types (Beroukhim et al., 2010), the
fact that increased copies of MYC are often accompanied by co-
ampliﬁcation of an adjacent non-coding locus, PVT1 is not fully
appreciated nor understood (Asker et al., 1988; Shtivelman and
Bishop, 1989; Bakkus et al., 1990;Minarovits et al., 1990; Figure 1).
Furthermore, chromosomal translocations that appear to target
MYC are often found in Burkitt’s lymphoma (BL) and other non-
Hodgkin’s lymphoma types, but a subset of these lymphomas
(15–20%) exhibiting breakpoints as far as 300–400 kbdownstream
of MYC on 8q24, is a feature that complicates the hypothesis that
singular MYC is always the intended target.
In addition to MYC, the transcripts, POU5F1B and PVT1,
reside within the 128.0- to 130.0-Mb region of chr.8q24 most
often associated with GWAS, translocation, or integration events
(Figure 1). The POU5F1B gene was long considered as a pseudo-
gene (POU5F1P1), however, a recent report now proposes that it
could encode a weak transcriptional activator (Kastler et al., 2010).
The PVT1 locus expresses several alternatively spliced non-coding
transcripts (Shtivelman et al., 1989; Huppi et al., 1990; Shtivelman
and Bishop, 1990) and PVT1 is the host to a cluster of microR-
NAs (miR-1204∼ 1208; Huppi et al., 2008). Nevertheless, no clear
functional role for any of these transcripts has been identiﬁed
and the paucity of coding region genes within this chromoso-
mal region has lead to its description as the “8q24 gene desert”
(Ghoussaini et al., 2008; Wasserman et al., 2010). In this review
we discuss the growing evidence that the 8q24 gene desert in
fact, has a complex pattern of transcription that, in addition to
MYC, should be considered when assaying for disease candidate
loci.
SNPs ACROSS THE 8q24 REGION ARE ASSOCIATED WITH
DISEASE-RISK
Several years ago, our laboratory and others (Rothberg and Otto,
1995; Siwarski et al., 2001) identiﬁed SNPs within the coding
region of MYC (S11N, CAA-33, and S288K). For one of the SNPs
(S288K), we were able to follow the inheritance of the rare non-
synonymous variant allele in a small family pedigree and compare
expression of MYC between the two alleles. Our report high-
lighted the possibility of reduced expression from two rare variant
MYC alleles (S288K and CAA-33) and thus, demonstrated for
the ﬁrst time, differential expression levels of germline MYC alle-
les (Siwarski et al., 2001). At the time, we could not distinguish
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FIGURE 1 |The 8q24 gene desert. Shown along the 1.8-Mb region of
human chromosome 8q24 (128.0Mb thru 129.8Mb) are the extent of the
protein encoding MYC transcript (blue), the lincRNA PVT1 (dark blue), the
putative lincRNA PRNCR1 (dark blue), the less deﬁned POU5F1P1
transcript (light blue), and the microRNAs, miR-1204 through miR-1208.
Also depicted are the locations of GWAS deﬁned SNPs (1–28) associated
with disease susceptibility (seeTable 1 for details). The bars denote
focused regions of ampliﬁcation (shown in red), chromosomal translocation
(blue), viral integration (yellow), or deletion (green) that have been observed
in different tumor types (see text for details).
whether reduced MYC expression was due to the differential bind-
ing of transcription factors (such as YY1) to the actual SNP
sequence or whether associated 5′ or 3′ base changes accompa-
nied the presence of these alleles. The limitations of this study
were the small size of the cohort, coupled with the inability to ﬁnd
the rare variant outside of this family. However, with develop-
ment of high throughput, population-based SNP analysis, GWAS
are empowered with the ability to avoid false positive discovery
through study of large, well-documented case control and cohort
groups that avoid bias as a result of for example, survivorship and
sample integrity.
One of the ﬁrst cancer susceptibility GWAS to be published
linked prostate cancer susceptibility to SNP variants in the region
of chr.8q24, far upstream of MYC in the Icelandic population
(Amundadottir et al., 2006). Subsequent reports from the study
of Caucasian men in Sweden and the US further conﬁrmed the
linkage to prostate adenocarcinoma and narrowed the region of
risk to two alleles, the −8 allele at the marker DG8S737 and the
A allele of rs1447295 (Amundadottir et al., 2006). The incidence
of the DG8S737 marker was also increased in patients at risk for
prostate cancer in an independent study of African Americans but
this study also suggested that differences in the overall frequency
of the DG8S737 allele in Caucasians versus African Americans
might bias the link to prostate cancer (Freedman et al., 2006). As
a result of the many additional studies of SNPs from the region
of chr.8q24 (Gudmundsson et al., 2007; Haiman et al., 2007; Yea-
ger et al., 2007; Eeles et al., 2008; Ghoussaini et al., 2008; Thomas
et al., 2008), several sub-regions of susceptibility can be assigned
to prostate cancer risk in a region of ∼2.7Mb of DNA extending
from a position centromeric to POU5F1B to include a region of
several hundred kb of DNA proximal of MYC (Figure 1; Table 1).
While many of the chr.8q24 associated SNPs were originally
identiﬁed as susceptibility markers for prostate cancer, additional
SNPs in the region of chr.8q24 have now been associated with
many other cancers (Figure 1; Table 1). For example, two SNPs
(i.e., rs13281615 and rs1562430) are linked to breast cancer (Eas-
ton and Eeles, 2008), and the SNP rs9642880 has been uniquely
associated with bladder cancer (Ghoussaini et al., 2008). Some
SNPs including rs10505477 (positioned at 128.40Mb), rs1562430
(position 128.38Mb), and rs6983267 (position 128.41Mb) are
found to be associated with increased susceptibility in multiple
cancers whereas some SNP variants appear to be unique suscepti-
bility markers to a singular cancer type. An example of the unique
cancer based SNP is rs2456449, which to date, has only been asso-
ciated with susceptibility to B-cell chronic lymphocytic leukemia
(Crowther-Swanepoel et al., 2010). In addition to the SNP vari-
ants located to the proximal (5′) side of MYC, a few susceptibility
variants have been identiﬁed 3′ of MYC in the PVT1 region.
A number of SNP variants for ovarian cancer have been iden-
tiﬁed on both the 5′ (Ghoussaini et al., 2008) and 3′ side of MYC
(Goode et al., 2010), respectively. Although this might implicate
MYC as the central target in ovarian cancer, some doubt as to the
strength of these GWAS studies has been raised, as the positioning
of the risk alleles appears to be report speciﬁc (White et al., 2010;
Braem et al., 2011). The fact that ovarian cancer is a heterogeneous
disease may also be a factor leading to the lack of reproducibility in
assigning ovarian cancer risk. Nevertheless, independent ﬁndings
such as, frequent ampliﬁcation in ovarian cancer (see below) still
suggests that the 8q24 locus may be an important region in the
progression of ovarian cancer.
The presence of multiple loci associated with susceptibility to
different cancer speciﬁcities raises another provocative question
as to whether the clustering of many 8q24 SNP variants could
be pleiotropic. For instance, is the region of 8q24 unique in the
genome in harboring many cancer risk loci or will additional
regions of multiple cancer risk eventually be identiﬁed. A pos-
sible clue comes from a study of disease susceptibility in end stage
renal disease (ESRD). A series of SNP variants located within the
PVT1 region have been identiﬁed as candidate loci for ESRD in
type 1-diabetes (Hanson et al., 2007). Further characterization of
the PVT1 gene in diabetic kidney disease studies suggest a possible
molecular mechanism for the non-coding PVT1 gene in extracel-
lular matrix (ECM) accumulation (Alvarez and DiStefano, 2011).
More importantly, it relies on a function of PVT1 independent of
MYC, in the progression of ESRDand it underscores the possibility
that the 8q24 locus is multifaceted and not simply dominated by a
single regulatory element or gene. Interestingly, diabetes and can-
cer are known to share common risk factors although for prostate
cancer in particular, the risk is inversely correlated with diabetes
(Giovannucci et al., 2010).
The challenge of population-based cancer susceptibility in
GWAS is the establishment of a connection between the posi-
tion of SNP variants and functionality. This is critical because
most cancer-associated SNP variants have been found to be syn-
onymous, mapping to regions of intervening DNA, often very
distant from candidate protein-coding genes. This has been espe-
cially apparent in the chr.8q24 region where MYC resides as
the most likely candidate gene target yet establishing a func-
tional correlation with MYC expression has been surprisingly
inconsistent.
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Table 1 | SNPs associated with risk in 8q24.
SNP Disease Position P -value Reference
rs1016343 Prostate cancer 128093297 1×10−7 Eeles et al. (2008)
rs16901979 Prostate cancer 128124916 3×10−14 Gudmundsson et al. (2007)
rs2456449 Chronic lymphocytic leukemia 128192981 8×10−10 Crowther-Swanepoel et al. (2010)
rs16902094 Prostate cancer 128320346 6×10−15 Gudmundsson et al. (2007)
rs378854 Prostate cancer 128323819 Meyer et al. (2011)
rs13281615 Breast cancer 128355618 5×10−12 Easton and Eeles (2008)
rs1562430 Breast cancer, prostate cancer 128387852 6×10−7 Turnbull et al. (2010)
rs10505477 Ovarian cancer 128407443 2×10−3 Ghoussaini et al. (2008), Zanke et al. (2007)
Colon cancer 3×10−11
rs10808556 Ovarian cancer 128413147 Ghoussaini et al. (2008)
rs6983267 Ovarian cancer 128413305 9.9×10−3 Yeager et al. (2007), Ghoussaini et al. (2008), Eeles
et al. (2008), Thomas et al. (2008), Tomlinson et al.
(2007), Berndt et al. (2008)
Colon cancer 1×10−14
Prostate cancer 9×10−13
rs7837328 Colon cancer 128423127 Berndt et al. (2008)
rs7000448 Prostate cancer 128441170 Ghoussaini et al. (2008)
rs1447295 Prostate cancer, esophageal cancer 128485038 2×10−19 Gudmundsson et al. (2007), Yeager et al. (2007),
Lochhead et al. (2011)
rs4242382 Prostate cancer 128517573 3×10−19 Thomas et al. (2008)
rs7017300 Prostate cancer 128525268 Yeager et al. (2007)
rs10090154 Prostate cancer 128532137 Cheng et al. (2008)
rs7837688 Prostate cancer 128539360 Yeager et al. (2007), Berndt et al. (2008)
D8S1128 Type II diabetes 128595148 2×10−3 An et al. (2006)
rs9642880 Bladder cancer 128718068 7×10−12 Ghoussaini et al. (2008), Kiemeney et al. (2008)
rs11993333 End stage renal disease (type I diabetes) 128992487 1.3×10−3 Hanson et al. (2007)
rs2720709 End stage renal disease (type I diabetes) 129058356 2×10−5 Hanson et al. (2007)
rs2648862 End stage renal disease (type I diabetes) 129061785 Hanson et al. (2007)
rs2608053 Hodgkin’s lymphoma 129075832 1.16×10−7 Enciso-Mora et al. (2010)
rs1499368 End stage renal disease (type I diabetes) 129094589 6.1×10−3 Hanson et al. (2007)
rs2019960 Hodgkin’s lymphoma 129192271 1.26×10−13 Enciso-Mora et al. (2010)
rs1516982 Ovarian cancer 129533646 Goode et al. (2010)
rs10088218 Ovarian cancer 129543949 8×10−15 Goode et al. (2010)
rs10098821 Ovarian cancer 129559228 Goode et al. (2010)
MYC
The MYC gene (128748315–128753680) is comprised of three
exons; exon 1 is non-coding, exons 2 and 3 are protein-coding
(for review see Pelengaris and Khan, 2003). The translation start
signal (TSS) in exon 2 generates a protein of 439 amino acids
(64 kDa). Alternative translational initiation start sites are capa-
ble of generating a larger protein, p67 and a shorter one, MYC.
Transcription of the MYC gene initiates from one of two pro-
moters, P1 or P, and there are several well-characterized elements
that bind the MYC promoter including CT, FUSE, TFIIH, and
FIR. When chromosomal translocations displace P1 and P2 with
the immunoglobulin enhancers (as observed in BL), de-regulated
MYC expression persists from a series of cryptic promoters within
the intron.
MYC is one of the most studied oncogenes stemming from its
association with a large number of diseases and indeed, a link to
MYC expression for alleles associated with particular SNPs would
be a ﬁrst candidate gene of choice. In concert with this hypothesis,
Sole et al. (2008) found consistent up-regulated expression of MYC
in normal prostate samples with regard to at least one risk locus
(rs1447295). However, another group (Pomerantz et al., 2009a)
failed to ﬁnd any correlation between MYC expression and a risk
allele (including rs1447295) in their normal prostate samples. Pos-
sible reasons for the inconsistencies could be differences in tissue
purity or integrity of RNA, but a third study now suggests that the
ideal window to examine the affects of risk allele and expression
of MYC may be earlier in the formation of the tumor than what is
usually tested (Wasserman et al., 2010). MYC expression in associ-
ation with disease-risk alleles has also been examined in colorectal
tissues and once again, three independent studies have failed to
establish any correlation between MYC expression and the risk
alleles (Zanke et al., 2007; Pomerantz et al., 2009b; Tuupanen et al.,
2009). In a more detailed study of a single risk allele rs6983267 in
colorectal samples,Wright et al. (2010) dissected MYC expression
into speciﬁc chromosomes and found MYC expression to be allele
speciﬁc. As noted above, SNPs both upstream and downstream of
MYC have been linked to ovarian cancer suggesting MYC is the
target gene in this case. However, studies of risk-associated alleles
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in ovarian cancer have failed to showcorrelationwithMYC expres-
sion (Goode et al., 2010). Thus, the issue of association between
risk alleles and MYC expression remains inconsistent.
The co-localization of epigenetic landmarks with SNP variants
could also be a source of transacting regulation of nearby genes
such asMYC. In fact, chromatin immunoprecipitation studies have
found acetylation and histone markers consistent with regulatory
activity for one SNP variant (rs6983267) in colorectal cancer and
reporter assays have shown allele speciﬁc enhancement of MYC
expression in colorectal cancer lines (Pomerantz et al., 2009b;
Wright et al., 2010). Several other SNP variants in prostate and
breast cancer show similar properties in a tissue speciﬁc fashion
(Ahmadiyeh et al., 2010). Further, the rs6983267 risk allele has
been shown to bind avidly to the TCF7L2 transcription factor
compared to the non-risk allele (Sotelo et al., 2010). The question
is, do these enhancers interact with MYC or with other genes in
the chr.8q24 region or with transacting elements elsewhere in the
genome? Several studies have now demonstrated direct binding
of the rs6983267 risk region with promoter regions of MYC in
colorectal cancer cell lines (Pomerantz et al., 2009b; Wright et al.,
2010) and prostate cancer cell lines (Sotelo et al., 2010). However,
the results in the prostate study are conﬂicting in that the greatest
enhancer activity was found not in association with the risk locus
rs3983267 but with a neighboring region of DNA (Sotelo et al.,
2010). Furthermore, enhancer activity associated with rs3983267
was seen only in the presence of both TCF7L2 and CTNNB1 and
reporter assays showed enhanced expression with the non-risk
allele compared to the risk allele. Nevertheless, Wasserman et al.
(2010) are able to show that the risk allele does indeed bind more
avidly than the non-risk allele in vivo (prostate and coagulating
glands). With the inconsistency of these results, it is apparent that
the lack of correlation between MYC expression and the presence
of the risk allele in prostate cancer would indicate that either the
window of accessibility is earlier in the development of the tumor
or the gene target is not MYC. Consistent with this argument are
the studies of Cole and colleagues (Wright et al., 2010) who show
that the rs3983267 enhancer has signiﬁcant binding activity to
both MYC and also the neighboring PVT1 promoters. While this
could be explained as co-regulated expression of both MYC and
PVT1, it is also possible that the intended target in some of these
malignancies is something other than MYC. For example, in an
examination of expression in prostate cancer specimens, signif-
icant increased expression was observed with at least one PVT1
transcript variant (Pomerantz et al., 2009b).
PVT1
The “plasmacytoma variant translocation” or PVT1 locus was
originally deﬁned as a cluster of chromosomal translocation or
viral integration breakpoints located several hundred kilobases
(kb) downstream of MYC in B-cell or T cell lymphomas (Erikson
et al., 1983; Webb et al., 1984). The term “variant” referred to the
frequency of chromosomal breakpoints in BL or mouse plasma-
cytoma found in the PVT1 region (10–20%) compared to those
breakpoints found near MYC (80–90%). Although the break-
points fuse a segment of PVT1 with immunoglobulin light chain
gene, it was originally thought that interruption of PVT1 simply
lead to de-regulated expression of nearby MYC. However, lack of
consistent up-regulation of MYC in a number of lymphomas, lead
to the search and discovery of PVT1 transcripts in both human and
mouse (Shtivelman et al., 1989; Huppi et al., 1990). The human
PVT1 transcript starts with either exon 1a (128806779) or exon 1b
(128808208)∼40–42 kb 3′ of the MYC transcript and with exten-
sive alternative splicing, the PVT1 transcript can extend 1.1Mb
distal to MYC to create transcripts of between 2.7 and 3.3 kb in
length (Figure 2). Among the human PVT1 transcripts identiﬁed,
expression of exon 1a far out-weighs the utilization of exon 1b.
Most importantly, exons 1a and 1b are mutually exclusive in that
they have not been found spliced together in cDNAs. In fact, it
is possible that exon 1b is only expressed in malignant cell lines
containing ampliﬁed PVT1 (Guan et al., 2007). Although the most
commonly used exons are 1a, 2, 3b, 4b, 7, 8, and 9, it should be
emphasized that alternative splicing in different tissues makes it
difﬁcult to assign a single reference consensus sequence (Figure 2).
One of the most remarkable features of the PVT1 locus since the
discovery of cDNA clones in the early 1990s is the conservation of
transcriptional activity in this region across synteny. PVT1 tran-
scripts have been cloned from rat (Koehne et al., 1989; Tsichlis
et al., 1989), mouse (Huppi et al., 1990), and human (Shtivelman
et al., 1989) and yet no consistent protein encoding open reading
frames could be established despite the utilization of as many as 8–
10 alternative exons. Despite the consistent localization of PVT1
transcripts close to MYC in several different species, the incon-
sistency of the location of exons in these species coupled with a
complete lack of sequence conservation across species suggested
early on to investigators, including ourselves, that PVT1 was not
translated as a protein product from the normal transcript. Thus
PVT1 became an early example of a non-coding RNA (for a cur-
rent review of non-coding RNA see Esteller, 2011), similar to the
loci H19 (Brannan et al., 1990) and XIST (Brockdorff et al., 1992;
Brown et al., 1992). Even though suggestionsweremade that PVT1
could act as a regulatory RNA, a lack of deﬁned function left PVT1
transcription as a curiosity (Huppi and Siwarski, 1994).
Our improved understanding of the importance of long RNAs
(lincRNAs) and the ﬁnding of multiple disease-risk SNPs close to
the PVT1 have prompted renewed interest and investigation into
this locus. Itwas a search formethylated chromatin (H3K4me3and
H3K36me3) that led to the prediction, and ultimately, the identi-
ﬁcation of three mouse PVT1 cDNAs (Pvt1-201, Pvt1-202, Pvt1-
203) as potential lincRNAs (Guttman et al., 2009). As a human
lincRNA counterpart in the PVT1 region has been predicted from
the Ensembl lincRNA annotation pipeline (AC103705.1-201 in
Figure 2) there is a potential for lincRNA based PVT1 function,
but this still needs to be validated in vivo. Recent evidence has also
noted PVT1 as among the top fold decrease in expression during
the transition from induced pluripotent stem cells (iPSCs) to neu-
rons (Lin et al., 2011). Additional evidence for a functional role
for PVT1 has also come from the study of the effect of silencing
of PVT1 transcripts via RNAi. Speciﬁcally, Gray and colleagues
were able to induce apoptosis in ovarian or breast cell lines fol-
lowing silencing of PVT1 in cell lines with ampliﬁed chr.8q24 but
they found no apoptosis in non-ampliﬁed cell lines (Guan et al.,
2007). Why 8q24 ampliﬁed cell lines as opposed to non-ampliﬁed
cell lines are uniquely susceptible to silencing of PVT1 is puz-
zling and will need further clariﬁcation. Evidence that PVT1 was
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FIGURE 2 |Transcripts from the 8q24 region downstream of MYC. MYC
(blue) is used as the anchoring position for depicting the series of alternative
spliced transcripts from PVT1 and the location of miRNAs (miR-1204 through
miR-1208 ). The positions of the exons are located with respect to the
chromosome 8 address (128.80–129.20Mb) and are colored with respect to
whether they are frequently used (dark blue), infrequently used (yellow), or
part of a putative lincRNA (orange). Shown are the PVT1 exon composition
observed in cDNA clones from the tissues indicated [Leu1, Leu2, 4, Leu5
(Huppi, unpublished), A8, B6, B4, B9 (Guan et al., 2007) Y2, NR_003367
(Shtivelman et al., 1989), AC103705.1-201 (Ensembl annotation lincRNA
pipeline)]. Only unique variants have been listed to abbreviate the list. The
reader is encouraged to review the complete list online (UCSC database).
acting independently of MYC in these experiments came from
the fact that inhibition of MYC alone failed to induce apoptosis.
Further, a recent publication (Meyer et al., 2011) has identiﬁed
a risk variant rs378854 that is located within a DNase hypersen-
sitive site and within a repetitive region ∼0.5Mb upstream of
the PVT1 promoter (also upstream of MYC). This region had
not been detected previously due to the need to extract repetitive
sequences from DNase analysis. This risk allele (rs378854) appears
to be prostate tissue speciﬁc. Binding of the transcription factor
YY1 is observed on the risk variant and further studies with chro-
matin conformation capture (3C) have shown the ability of this
region to interact long range with MYC, PVT1 (but not FAM84B
a gene located centromeric of POU5F1B). This study also corre-
lated reduced expression of PVT1 (in the absence of a change in
MYC expression) with the loss of YY1 binding to the risk allele.
Another hint at a possible functional role for PVT1 has been found
in a transposon-based genetic screen of Gemcitabine sensitivity in
pancreatic cells (You et al., 2011). Although this study needs to be
validated, transposon-based inactivation of the PVT1 transcript
alone (independent of MYC) resulted in increased sensitivity to
Gemcitabine in the pancreatic cell line ASPC-1 whereas over-
expression of PVT1 led to increased cellular proliferation even
in the presence of Gemcitabine.
The discovery of miRNAs several years ago also encouraged
us to re-examine the PVT1 locus for the presence of RNAs that
may have been too small to be detected in the original cDNA
cloning studies. Our detailed study of the reﬁned region of 400 kb
surrounding the PVT1 region lead to the discovery of a cluster
of miRNAs (miR-1204∼ 1208) residing within the PVT1 locus
but not overlapping with any PVT1 exons (Huppi et al., 2008).
One miRNA, miR-1204 resides adjacent to the little used exon 1b
of PVT1 and includes a very short overlapping segment with the
exon. From 5′ RACE experiments, it is clear that miR-1204 and
PVT1 share promoters and probably share regulatory elements
for the most part as expression of both PVT1 and miR-1204 often
appear to respond together (Barsotti et al., 2011). Each of the other
miRNAs, miR-1205∼ 1208, appear to be differentially regulated
from PVT1 and miR-1204 (Huppi et al., 2008). Interestingly, in
the study of prostate cancer specimens and the risk allele rs378854,
Ponder and colleagues observe evidence of a possible correlation
between expression of miR-1208 and prostate cancer (Meyer et al.,
2011), although this ﬁnding will need further study. In another
recent study of human diploid ﬁbroblasts, miR-1204 was noted
as having the greatest increase in expression levels among miR-
NAs in senescent versus early passage ﬁbroblasts (Marasa et al.,
2010) and miR-1204 was also noted as showing increased expres-
sion during the iPSCs neuronal differentiation (Lin et al., 2011).
Although preliminary, these ﬁndings implicate miR-1204 in the
subset of miRNAs associated with suppression of tumor growth.
Our recent ﬁndings have shown that PVT1 and miR-1204 are both
responsive to Daunorubicin treatment in a number of cell lines
including colon, ﬁbroblast, and lymphoid (Barsotti et al., 2011).
As the presence of a p53 binding site in the promoter region of
PVT1 and miR-1204 is the basis for the Daunorubicin mediated
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response to DNA damage in several different tissue types, these
results implicate a pro-survival role for PVT1 consistent with the
ﬁndings of You et al. (2011) in the Gemcitabine experiments in
pancreatic cells. In contrast, activation of miR-1204 by binding
of p53 appears to be anti-proliferative suggesting a very interest-
ing series of opposing actions of PVT1 versus miR-1204. Further
studies on the apparent opposing actions of PVT1 and miR-1204
are being carried out.
Studies in type 1-diabetes ESRD (Millis et al., 2007; Alvarez
and DiStefano, 2011) have ruled MYC out as the candidate
gene whereas certain variants of the PVT1 transcript were highly
expressed in renal cells and speciﬁcally up-regulated in hyper-
glycemic conditions. Furthermore, silencing of PVT1 appeared
to reduce the expression of speciﬁc genes, including FN1, COL4,
TGFB1, andPAI-1 that are involved in the composition of the ECM
affecting glomerular ﬁltration (Alvarez and DiStefano, 2011). Per-
haps for the ﬁrst time, a speciﬁc function might be assigned to the
non-codingPVT1 transcript independent of MYC, but this ﬁnding
will need to be conﬁrmed.
POU5F1B AND PRNC1
A series of transcripts that map centromeric to the GWAS
SNP variants, 1.2Mb proximal to MYC and just distal to
FAM84B on chr.8q24 are associated with POU5F1B (128427857–
128429455). POU5F1B was originally considered to be a pseudo-
gene (POU5F1P1) of OCT4, an important transcription factor
involved in stem cell pluripotency and reprogramming. Extensive
5′ RACE experiments have identiﬁed several alternatively spliced
transcripts (Kastler et al., 2010), differing in their TSS that all seem
to splice to a single main exon carrying the ORF. The transcript
variant with the most distant TSS actually starts within the intron
of FAM84B generating a transcript that extends over a region
of 860 kb. There is evidence that transcription of POU5F1B is
increased in many cases of prostate cancer, whereas some com-
mon prostate cell lines (i.e., DU-145, PC-3) do not appear to
express the transcript. Kastler et al. (2010) have used an antibody
to Oct4 assuming that Oct4 is not expressed in prostate tissue to
demonstrate that a protein is indeed detectable in prostatic tissue.
However, the signal for this protein is weak and direct demonstra-
tion of a protein speciﬁc to POU5F1B needs to be performed
to validate these results. In addition, a long non-coding RNA
(PRNCR1) of 13 kb was recently isolated from one of the recog-
nized susceptibility regions just distal to the SNPvariant rs1456315
(Chung et al., 2011).Up-regulated expression of PRNCR1has been
noted in a number of microdissected prostate cancer samples and
prostate intraepithelial neoplasia compared tonormal adjacent tis-
sue (Chung et al., 2011). Further validation of this transcript will
be needed to determine whether it plays a role in prostate cancer
or other cancers.
CANCER-ASSOCIATED GENOMIC ALTERATIONS AND THE
8q24 REGION
In addition to the clustering of cancer-associated SNPs that map
to chr.8q24, the 8q24 region has recently been identiﬁed in a large-
scale study across human cancers as the most frequently ampliﬁed
region (14%; Beroukhim et al., 2010). Detailed studies of indi-
vidual cancer type studies have also revealed extensive evidence
of gene ampliﬁcation involving the chr.8q24 region, often with
reference to increased MYC copy number and/or increased MYC
expression. Although most reports focus primarily on MYC as the
target of these ampliﬁcation events, more detailed analyses with
additional probes often ﬁnds adjacent regions of 8q24within these
amplicons. MYC ampliﬁcation, for example, is considered to be a
prognostic marker of early stage lung adenocarcinoma (ADC) as
MYC ampliﬁcation correlates with poor prognosis (Iwakawa et al.,
2011). Speciﬁcally ﬁve sub-regions of ampliﬁcation were deﬁned
in the chr.8q24 region including a MYC containing sub-region
three in 10.8% of primary lung ADCs (n = 65) and 25% of lung
ADC cell lines (n = 40). While PVT1 and miR-1208 mapped to
what the authors refer to as ampliﬁcation sub-region four,no other
sub-regions (1, 2, or 5) corresponded to any candidate transcripts.
In a sequencing study of the lung ADC cell line, NCI-H2171, a
fusion gene comprised of CHD7 and PVT1 was identiﬁed (Camp-
bell et al., 2008). Subsequent fusions between CHD7 and exon 1
of PVT1 were also identiﬁed in LU-135 (Pleasance et al., 2010). In
another large study of lung ADC (n = 371), ampliﬁcation identi-
ﬁed by “Genomic Identiﬁcation of Signiﬁcant Targets in Cancer”
(GISTIC) analysis focused on the region between 129.18 and
129.34Mb (q = 9.06× 10−13) that refers to MYC as the affected
proto-oncogene (Weir et al., 2007). The more precise localization
of this ampliﬁcation is actually the region of distal PVT1 and
miR-1208 (Figure 1 – Ampliﬁcation-2).
Genomic Identiﬁcation of Signiﬁcant Targets in Cancer analy-
sis in a study of 52 ovarian tumors found 59% with a gain of
MYC and PVT1 but only signiﬁcant over-expression of PVT1 rel-
ative to normal samples (Haverty et al., 2009). Consistent with
these results are the combined studies of ovarian and breast can-
cer by Gray and colleagues that show PVT1 and MYC contribute
independently to pathogenesis with a strong correlation to overall
chr.8q24 ampliﬁcation (Guan et al., 2007). RNAi-mediated silenc-
ing in ovarian and breast cell lines showed reduced proliferation in
8q24 ampliﬁed cell lines for either MYC or PVT1, whereas silenc-
ing of just PVT1 increased apoptosis and only in cell lines with
ampliﬁcation of 8q24. However, as mentioned above, no mech-
anistic explanation for the speciﬁcity of this observation in cell
lines with ampliﬁed 8q24 has emerged as yet. High-resolution
comparative genomic arrays of chromosome 8q have also been
utilized in a study of gastroesophageal junctionADCs that include
esophagus and cardia cancers (van Duin et al., 2007). Three com-
monly overexpressed regions of genomic gain were identiﬁed on
chr.8q24 with the most distinctive encompassing MYC at 128–
132Mb. The other regions that were identiﬁed are between 124
and 127Mb (referred to as Region 1) that included FAM84B
and a region far downstream between 142 and 146Mb (referred
to as Region 4). In studies of expression of gastric esophageal
junction tumors versus normal adjacent tissue, van Duin et al.
(2007) saw a signiﬁcant increase in expression of MYC, but
not FAM84B. Many examples of ampliﬁed chr.8q24, particularly
those from older studies have exclusively compared expression
of MYC without the beneﬁt of knowing additional transcripts
may exist. In this case, a large bulk of the literature contains
evidence of chr.8q24 ampliﬁcation in combination with MYC
over-expression (Borg et al., 1992; Mangano et al., 1998; Kim
et al., 2006). One of the ﬁrst studies of PVT1 transcription by
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Shtivelman and Bishop (1989), intuitively suggested that PVT1
or at least the ﬁrst exon of PVT1 may co-amplify with MYC
and the expression of both MYC and PVT1 transcripts may
be coordinately up-regulated. These ﬁndings arose from stud-
ies of ampliﬁed chr.8q24 in colon, SCLC, and neuroepithelioma
cell lines. Additional studies also found co-ampliﬁcation of the
ﬁrst exon of PVT1 and MYC in 2/26 cases of multiple myeloma
(Bakkus et al., 1990). With the high frequency of co-ampliﬁcation
that seems to be focused on the immediate region surrounding
MYC, PVT1, exons 1a and 1b, and miR-1204 in many different
tumors, we have designated this region 1 of ampliﬁcation in 8q24
(Figure 1 – Ampliﬁcation-1).
CHROMOSOMAL TRANSLOCATION
The 8q region is among the earliest cytogenetic examples of
a human chromosomal translocation (Zech et al., 1976). The
T(8:14) translocation and subsequent variant translocations of
T(8:22) and T(2:8) became the hallmark lesion in BL, a form of
non-Hodgkin’s lymphoma prevalent in sub-Saharan regions of
Africa. Interestingly, it was the similar mouse B-cell disease, the
plasmacytoma that suggested the ﬁrst molecular recognition of
MYC as the targeted fusion gene in the chr.8q24 region (Shen-Ong
et al., 1982). Although other forms of non-Hodgkin’s lymphoma
such as a subset of diffuse large B-cell lymphoma, follicular lym-
phoma, or mantle cell lymphoma may also present with MYC
translocations, the predominance of the chr.8q24-based translo-
cation in BL has become the hallmark lesion forWHO designation
as BL. While the fusion in most (frequency of 80%) of these dis-
eases is between the immunoglobulin (Ig) heavy chain and MYC,
variant translocations (at a frequency of 20%) also implicating
the chr.8q24 region but with a different fusion partner (Ig light
chain genes) are also recognizable BL speciﬁc lesions. The target
of essentially all variant translocations to the Ig light chain genes
is PVT1. Some T cell leukemias also carry T(8;14) translocations
but the fusion partner is one of the TCR loci (TCR alpha or delta
juxtaposed to either MYC or PVT1. In a very interesting study
describing the cytogenetic events associated with a rare disease
of hematodermic neoplasm, the authors have identiﬁed a series
of changes including deletion of the region 3′ of PVT1 (Jardin
et al., 2009). What they report is an arrest of plasmacytoid den-
dritic cells at the G1/S transition possibly connected to the loss of
several miRNAs (miR-1206, miR-1207, and miR-1208) from the
Chr.8q24 cluster (Jardin et al., 2009).
VIRAL INTEGRATION
Infection with human papilloma virus (HPV) is believed to be
important in the pathogenesis of anogenital carcinomas and other
epithelial carcinomas (zur Hausen, 2000). It is also believed the
HPV will persist in an epifocal state in early dysplasia with the
presence of E6 and E7 proteins capable of interfering with cellular
controlmechanisms. Eventual integrationof HPV into the genome
is found in advanced and high risk carcinomas that might suggest
the additional recruitment of cellular oncogenes in the trans-
formation process. However, the essential randomness of HPV
integration throughout the entire genome makes the argument of
a speciﬁc target tenuous at best. The most common site of HPV
integration in genital neoplasia (10.7% or 26/243) is the Chr.8q24
region with two sub-clusters of integration sites around 500 and
60 kb upstream of MYC (Durst et al., 1987; Popescu et al., 1987;
Peter et al., 2006). Originally, it was thought that only HPV18 inte-
grated into the 8q24 locus (Ferber et al., 2003), but more recent
studies have documented HPV16 and HPV45 to be integrated
into the 8q24 region as well (Peter et al., 2006; Kraus et al., 2008).
In one of the most often-characterized cervical cancer cell lines,
HeLa, integration of HPV18 into the 8q24 locus was identiﬁed
with accompanying increased MYC expression. It now appears
that the basis for the over-expression of MYC in HeLa and other
ADCs with 8q24 integrated HPV sequences is co-ampliﬁcation of
MYC and adjacent sequences including PVT1a, miR-1204 with
the integrated viral sequences of HPV (Herrick et al., 2005; Peter
et al., 2006). An important histological distinction has been noted
in that ADCs frequently exhibit an 8q24 HPV integration whereas
squamous cell carcinomas contain other random chromosomal
integration events (Lombard et al., 1998; Peter et al., 2006). Thus,
it may not be the type of HPV found integrated at 8q24 that is so
important in the development of cervical CA, but the location and
the accompanying ampliﬁcation events.
SUMMARY
It is well known that the oasis is a small but signiﬁcant com-
ponent of the desert ecosystem. By analogy, it may be that the
presence of not just the MYC oncogene, but also the adjacent
loci of PVT1, PRNCR1, the miRNA cluster of miR-1204∼ 1208 or
POU5F1P1 represent a more comprehensive transcriptional oasis
in the 8q24 gene desert. In most studies involving the 8q24 locus,
the MYC proto-oncogene is the focus of attention as neighbor-
ing non-coding transcripts have struggled for the establishment
of functionality. However, it is often but not always the case that
increased MYC expression is accompanied by increased expres-
sion of the neighboring transcripts, principally PVT1. The reason
for this could be epigenetic (chromatin accessibility) or the sug-
gestion that at least in one case, MYC binds to the promoter of
PVT1, thereby activating PVT1 and miR-1204 transcription (Car-
ramusa et al., 2007). Another means of co-activating MYC, PVT1,
and miR-1204 derives from the observed enhancer binding activ-
ity of the rs3983267 risk region to the promoters of PVT1, MYC,
and miR-1204 (Wright et al., 2010). In at least one study of the
pathophysiology of ovarian and breast cancer, it has been shown
that MYC and PVT1 act independently and at least for PVT1, this
action is mediated through apoptosis (Guan et al., 2007). Further-
more, this action may be associated speciﬁcally with ampliﬁcation
of the 8q24 region. Induction of apoptosis by over-expression of
miR-1204 and perhaps the other miRNAs in the miR-1204∼ 1208
cluster as well suggests an anti-proliferative role for the miRNAs
independent of MYC (Barsotti et al., 2011). Obviously, it will
also be important to elucidate the speciﬁc nature of interactions
between the miR-1204∼ 1208 cluster and the non-coding PVT1
host transcript as well. An interesting genetic analog to the PVT1
region is human chromosome 13q14 that contains two miRNAs,
miR15a, miR-16-1, within the intron 4 of the host non-coding
transcript DLEU2 (Migliazza et al., 2001). Although the speciﬁc
role for DLEU2 is not understood, it appears that deletion of the
entire region is required in the development of an aggressive phe-
notype of chronic lymphocytic leukemia suggesting a combined
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role for miRNAs and a non-coding transcript (Klein et al., 2010).
In this paper, we have attempted to raise the awareness of other
transcripts besides MYC in the 8q24 region to emphasize possible
roles they may play as well in what appears to one of the most cited
regions (8q24) in the human genome.
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